Academic Journal
Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.
| Τίτλος: | Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece. |
|---|---|
| Συγγραφείς: | Tzanetakos C; Health Through Evidence, Athens, Greece., Vakouftsi VR; Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC), Athens, Greece., Mavridoglou G; University of Peloponnese, Kalamata, Greece., Angelopoulou A; Health Through Evidence, Athens, Greece., Gourzoulidis G; Health Through Evidence, Athens, Greece. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Jul 10; Vol. 17, pp. 1866461. Date of Electronic Publication: 2026 Jul 10 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Inflammatory Bowel Diseases*/epidemiology , Inflammatory Bowel Diseases*/therapy , Crohn Disease*/epidemiology , Crohn Disease*/therapy , Colitis, Ulcerative*/epidemiology , Colitis, Ulcerative*/therapy , Cost of Illness*, Greece/epidemiology ; Humans ; Male ; Female ; Adult ; Middle Aged ; Patient Reported Outcome Measures ; Quality of Life ; Aged ; Severity of Illness Index ; Surveys and Questionnaires ; Symptom Burden |
| Περίληψη: | Objectives: Despite therapeutic advances, inflammatory bowel disease (IBD) remains a lifelong debilitating disorder with substantial burden. The study aimed to investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece. Methods: Between October 2023 and January 2024, adult CD and UC patients who were members of Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC) and receiving advanced therapies completed a structured self-reported questionnaire. The survey collected data on sociodemographic characteristics, smoking status, comorbidities, disease activity, disease characteristics, current medications, and patient-reported outcomes (PROs; Short Inflammatory Bowel Disease Questionnaire [SIBDQ], Work Productivity and Activity Impairment [WPAI], Patient Health Questionnaire-9 [PHQ-9], treatment satisfaction and adherence). Both univariate and multivariate logistic regression analyses were performed to determine associated factors. Results: Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease. Overall, 76.4% reported impaired QoL, 30.3% work productivity loss, and 38.4% activity impairment, while nearly half exhibited moderate-to-severe depressive symptoms. Notably, 39.1% expressed dissatisfaction with their advanced therapy, while 10.9% reported reduced adherence. No significant differences were observed between CD and UC patients across PROs, except for adherence. Higher disease activity was consistently associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction. Conclusion: Despite advanced therapies, IBD burden remains substantial among Greek patients. A considerable proportion experience poor QoL, increased work impairment, significant depressive symptoms, and persistent disease activity. Marked treatment dissatisfaction, reported by four out of ten patients, highlights an unmet need for more effective management strategies. (Copyright © 2026 Tzanetakos, Vakouftsi, Mavridoglou, Angelopoulou and Gourzoulidis.) |
| Competing Interests: | Author V-RV is the president of HELLESCC. Authors GG and CT are owners of Health Through Evidence. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Contributed Indexing: | Keywords: Crohn’s disease; advanced therapies; disease burden; patient-reported outcomes; ulcerative colitis; unmet medical needs |
| Entry Date(s): | Date Created: 20260725 Date Completed: 20260725 Latest Revision: 20260725 |
| Update Code: | 20260725 |
| PubMed Central ID: | PMC13396155 |
| DOI: | 10.3389/fimmu.2026.1866461 |
| PMID: | 42500675 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1866461 |